Publication

Novel regulators of plasma lipid levels

Loaiza, N., Oldoni, F. & Kuivenhoven, J. A., Jun-2017, In : Current Opinion in Lipidology. 28, 3, p. 231-240 10 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Loaiza, N., Oldoni, F., & Kuivenhoven, J. A. (2017). Novel regulators of plasma lipid levels. Current Opinion in Lipidology, 28(3), 231-240. https://doi.org/10.1097/MOL.0000000000000416

Author

Loaiza, Natalia ; Oldoni, Federico ; Kuivenhoven, Jan A. / Novel regulators of plasma lipid levels. In: Current Opinion in Lipidology. 2017 ; Vol. 28, No. 3. pp. 231-240.

Harvard

Loaiza, N, Oldoni, F & Kuivenhoven, JA 2017, 'Novel regulators of plasma lipid levels', Current Opinion in Lipidology, vol. 28, no. 3, pp. 231-240. https://doi.org/10.1097/MOL.0000000000000416

Standard

Novel regulators of plasma lipid levels. / Loaiza, Natalia; Oldoni, Federico; Kuivenhoven, Jan A.

In: Current Opinion in Lipidology, Vol. 28, No. 3, 06.2017, p. 231-240.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Loaiza N, Oldoni F, Kuivenhoven JA. Novel regulators of plasma lipid levels. Current Opinion in Lipidology. 2017 Jun;28(3):231-240. https://doi.org/10.1097/MOL.0000000000000416


BibTeX

@article{b3bee282cbd74c138acb26543f6800fe,
title = "Novel regulators of plasma lipid levels",
abstract = "Purpose of reviewTo highlight very recent studies identifying novel regulatory molecules and mechanisms in plasma lipid metabolism.Recent findingsTwo novel regulatory mechanisms of LDL receptor (LDLR) intracellular trafficking have been described. The {"}COMMD/CCDC22/CCDC93'' and {"}Wiskott-Aldrich syndrome protein and SCAR homologue'' complexes were found to be involved in LDLR endosomal sorting and recycling, whereas the GRP94 was shown to protect LDLR from early degradation within the hepatocyte secretory pathway. Additionally, the transcription factors PHD1 and Bmal1 were identified to regulate LDL-C levels in mice by modulating cholesterol excretion. Important advances are reported on the relevance of two Genome Wide Association Studies hits: Reassessment of GALNT2 showed, in contrast to previous reports, that loss of GALNT2 reduces HDL-cholesterol in humans and other mammalian species, while phospholipid transfer protein was identified as an additional target of GALNT2. Tetratricopeptide repeat domain protein 39B was found to promote ubiquitination and degradation of Liver X receptor, and its deficiency increased HDL-cholesterol and cholesterol removal while also inhibiting lipogenesis in mice.SummaryThe unraveling of mechanisms how new factors modulate plasma lipid levels keep providing interesting opportunities to rationally design novel therapies to treat cardiovascular disease but also metabolic disorders.",
keywords = "atherosclerosis, HDL-cholesterol, LDL-cholesterol, lipid regulation, plasma lipids, triglycerides, CORONARY-HEART-DISEASE, FAMILIAL HYPERCHOLESTEROLEMIA, LDL, ATHEROSCLEROSIS, CHOLESTEROL, INHIBITION, LIPOPROTEINS, DEFICIENCY, METABOLISM, CLEARANCE",
author = "Natalia Loaiza and Federico Oldoni and Kuivenhoven, {Jan A.}",
year = "2017",
month = jun,
doi = "10.1097/MOL.0000000000000416",
language = "English",
volume = "28",
pages = "231--240",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "3",

}

RIS

TY - JOUR

T1 - Novel regulators of plasma lipid levels

AU - Loaiza, Natalia

AU - Oldoni, Federico

AU - Kuivenhoven, Jan A.

PY - 2017/6

Y1 - 2017/6

N2 - Purpose of reviewTo highlight very recent studies identifying novel regulatory molecules and mechanisms in plasma lipid metabolism.Recent findingsTwo novel regulatory mechanisms of LDL receptor (LDLR) intracellular trafficking have been described. The "COMMD/CCDC22/CCDC93'' and "Wiskott-Aldrich syndrome protein and SCAR homologue'' complexes were found to be involved in LDLR endosomal sorting and recycling, whereas the GRP94 was shown to protect LDLR from early degradation within the hepatocyte secretory pathway. Additionally, the transcription factors PHD1 and Bmal1 were identified to regulate LDL-C levels in mice by modulating cholesterol excretion. Important advances are reported on the relevance of two Genome Wide Association Studies hits: Reassessment of GALNT2 showed, in contrast to previous reports, that loss of GALNT2 reduces HDL-cholesterol in humans and other mammalian species, while phospholipid transfer protein was identified as an additional target of GALNT2. Tetratricopeptide repeat domain protein 39B was found to promote ubiquitination and degradation of Liver X receptor, and its deficiency increased HDL-cholesterol and cholesterol removal while also inhibiting lipogenesis in mice.SummaryThe unraveling of mechanisms how new factors modulate plasma lipid levels keep providing interesting opportunities to rationally design novel therapies to treat cardiovascular disease but also metabolic disorders.

AB - Purpose of reviewTo highlight very recent studies identifying novel regulatory molecules and mechanisms in plasma lipid metabolism.Recent findingsTwo novel regulatory mechanisms of LDL receptor (LDLR) intracellular trafficking have been described. The "COMMD/CCDC22/CCDC93'' and "Wiskott-Aldrich syndrome protein and SCAR homologue'' complexes were found to be involved in LDLR endosomal sorting and recycling, whereas the GRP94 was shown to protect LDLR from early degradation within the hepatocyte secretory pathway. Additionally, the transcription factors PHD1 and Bmal1 were identified to regulate LDL-C levels in mice by modulating cholesterol excretion. Important advances are reported on the relevance of two Genome Wide Association Studies hits: Reassessment of GALNT2 showed, in contrast to previous reports, that loss of GALNT2 reduces HDL-cholesterol in humans and other mammalian species, while phospholipid transfer protein was identified as an additional target of GALNT2. Tetratricopeptide repeat domain protein 39B was found to promote ubiquitination and degradation of Liver X receptor, and its deficiency increased HDL-cholesterol and cholesterol removal while also inhibiting lipogenesis in mice.SummaryThe unraveling of mechanisms how new factors modulate plasma lipid levels keep providing interesting opportunities to rationally design novel therapies to treat cardiovascular disease but also metabolic disorders.

KW - atherosclerosis

KW - HDL-cholesterol

KW - LDL-cholesterol

KW - lipid regulation

KW - plasma lipids

KW - triglycerides

KW - CORONARY-HEART-DISEASE

KW - FAMILIAL HYPERCHOLESTEROLEMIA

KW - LDL

KW - ATHEROSCLEROSIS

KW - CHOLESTEROL

KW - INHIBITION

KW - LIPOPROTEINS

KW - DEFICIENCY

KW - METABOLISM

KW - CLEARANCE

U2 - 10.1097/MOL.0000000000000416

DO - 10.1097/MOL.0000000000000416

M3 - Review article

C2 - 28333714

VL - 28

SP - 231

EP - 240

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 3

ER -

ID: 40678643